Home » Barry Bertolet Case Series

Dr. Barry Bertolet Case Series on Aggrastat 

Dr. Barry Bertolet presents a case series on the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs). 

The series is based on cases where patient treatment included Aggrastat (tirofiban hydrochloride) injection and is intended to be an educational resource for fellows and those who may not be familiar with the use of GPIs. 

These cases and testimonials are based on the experiences of a few people. Not all cases are identical. You are not likely to have similar results. 

Important Safety Information about the use of Aggrastat is provided below. 

Clinical studies performance with Aggrastat are provided in the full Prescribing Information. 

About Dr. Barry Bertolet

Dr. Barry Bertolet is an interventional cardiologist out of the Cardiology Associates of North Mississippi in Tupelo, MS. He is currently the Governor-Elect of the Mississippi chapter of the American College of Cardiology (ACC). He is also the founding member of the Mississippi Health Care Alliance which is an organization that has developed the nation’s first statewide system for care for both heart attack and stroke. Here he presents three cases where he used Aggrastat in his practice: 

  • Clot Develops Intracoronary During PCI
  • Patient Not Pre-Treated with Oral Anti-Platelet Therapy 
  • Poor Reperfusion after PCI in a patient with NSTEMI (coming soon)
Dr. Barry Bertolet was provided financial support from Medicure Inc. for the creation of these videos.

Clot Develops Intracoronary During PCI

A patient presents to the emergency department with dyspnea. Cardiac PET scan was performed which came back abnormal prompting a cardiac catheterization. During the procedure the patient developed an intracoronary clot. Watch to see what Dr. Bertolet did next. 

Patient Not Pre-Treated with Oral Anti-Platelet Therapy

A 56-year old female presents to the emergency department with acute respiratory distress and required intubation and mechanical ventilation. Her ECG was remarkable for inferior ischemia which prompted an urgent cardiac catheterization. Watch to see how Dr. Bertolet approached this case. 

Poor Reperfusion after PCI in a patient with NSTEMI

Coming soon! 

About Aggrastat

Aggrastat (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Aggrastat:

  • Offers protection during the delayed onset of the oral P2Y12 agents*
  • Has a rapid onset, achieving >90% platelet aggregation inhibition within 10 minutes1
  • Is reversible: platelets return to baseline function within 4 to 8 hours of discontinuation of infusion
  • Has no contraindication for patients on hemodialysis
  • Has no drug interactions with oral P2Y12 inhibitors*

* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding.

1 Mardikar HM et al. Am Heart J. 2007;154(344):e1-5
Aggrastat Pharmacy Product

See Cases from Other Interventional Cardiologists 

Check out the experience of other healthcare providers in the US that use Aggrastat to reduce the rate of thrombotic complications for their patients during PCI.

Dr. Saihari Sadanandan

Dr. Kevin Ariani

Dr. Deepak Talreja

Click to see the full list of available cases. 

Important Safety Information

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.